Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of…

Agreement comes as United Arab Emirates (UAE) and Israel Reach Historic Agreement to Fully Normalize Diplomatic Relations

HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today its subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC), a specialist healthcare center focused on cell therapy and regenerative medicine. Executives from both companies took part in a signing ceremony held via video conference between Israel and the UAE. The aim of the collaboration is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole. The collaboration between the parties was initiated by the Better Alternatives advisory firm.

The parties have agreed to exchange research results, share samples, join usage of equipment and testing, and other essential activities related to advancing the treatment and research of cell therapies for a broad range of medical conditions, including COVID-19.

ADSCC has been treating COVID-19 patients with stem cells sourced from the patients blood, by returning the cells back into the patients lungs as a fine mist through a nebulizer, a machine that helps a patient breathe in medicine through a mask or mouthpiece. Pluristem has treated patients with its placental PLX-PAD allogenic product via compassionate use programs in Israel and the U.S. and is currently conducting phase II studies in the U.S. and EU.

We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders. We see life science and regenerative medicine as a bridge for building peace, prosperity, and well-being in our region and for the entire world. I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. We are honored to be on the front line of this historical moment, stated Pluristem CEO and President Yaky Yanay.

Dr Yendry Ventura, General Manager of the ADSCC commented, Pluristem is a major player in the cell therapy field with years of experience, a unique platform and a robust clinical pipeline. We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole.

About Abu Dhabi Stem Cells CenterAbu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine, as well as delivering cutting-edge research on stem cells in the region. The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE. ADSCC specialties include immunology, hematology, clinical stem cell therapy, molecular biology, immunotherapy, orthopedics, and urology amongst others.

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the aim of the collaboration with the ADSCC is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole and the belief that it is its obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Dana RubinDirector of Investor Relations972-74-7107194danar@pluristem.com

See the original post:
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of...

Super Resolution – posted by Biophotonics.World at Biophotonics.World – Biophotonics.World

Image source: Leibniz IPHT

By: Sven Dring

When trying to visualize finest details in cells, standard light microscopes reach their limits. As a doctoral student, Rainer Heintzmann discovered a method that can break this barrier. Today, he has improved the technique of super-resolution microscopy to such an extent that it is useful for applications in biology and medicine

In order to observe living cells at work, researchers have to overcome a physical law. One of the fastest techniques to overcome the resolution limit of classical light microscopy is high-resolution structured illumination microscopy.

It makes details in cells visible that are about one hundred nanometers in size, one hundred millionth of a millimeter. However, translating the recorded data back into images used to take a lot of time. Rainer Heintzmann, together with a team of researchers from Bielefeld University, has developed atechnique that allowsthe image data to be reconstructed directly.This allows researchers to watch biologicalprocesses in the cellvirtually live. "It enables completely newimaging workflows that no other high-resolution microscopy method currently allows in this way," says Rainer Heintzmann.

The graphics helps computer gamers to have a great gaming experience. Researchers use it to observe the smallest cell components in action - in real time and at a very high frame rate. "The image data can be reconstructed about twenty times faster than it would take on a PC," explains Rainer Heintzmann, who already laid the foundations for the structured illumination method in high-resolution microscopy as a doctoral student in 1998. In cooperation with the Bielefeld research team led by Thomas Huser, he further developed the technique of Super-Resolved Structured Illumination Microscopy (SR-SIM).

In the fluorescence microscopic SR-SIM method, objects are irradiated with laser light using a special pattern. It excites special fluorescent molecules in the sample so that they emit light at a different wavelength. The microscopic image then shows this emitted light. It is first recorded in several individual images and then reconstructed as a high-resolution image on a computer. "The second step in particular has taken a lot of time so far," says Andreas Markwirth from Bielefeld University, first author of the study, which the research team published in the renowned journal "Nature Communications".

For the new microscope, the research team used parallelcomputer processes on modern graphics and was thus able to significantly accelerate image reconstruction. A minimum delay of 250 milliseconds is hardly noticeable to the hu- man eye. The raw data can also be generated faster with the newly researched microscope.

Structures that are invisible to conventional microscopes

"This makes it possible to measure samples quickly and to immediately adjust test conditions during an experiment instead of having to evaluate them afterwards," says Rainer Heintzmann, describing the practical benefits of the new technology. It is only through the rapid reconstruction of images that "this type of microscopy becomes really useful for applications in biology or medicine," says Thomas Huser. "Because the problem so far is: microscopes that offer sufficiently high resolution cannot display information at the appropriate speed".

For their study, the scientists tested the method on biological cells and recorded the movements of mitochondria, the energy centers of the cells that are about one micrometre in size. "We were able to generate about 60 frames per second that's a higher frame rate than in motion pictures. There are less than 250 milliseconds between measurement and image, so the technology allows real-time recordings," says Andreas Markwirth.

Until now, super-resolution methods have often been combined with conventional methods: A conventional fast microscope is used to find structures first. These structures can then be examined in detail with a super-resolution micro- scope. "However, some structures are so small that they cannot even be found with conventional microscopes, for example special pores in liver cells. Our method provides both high resolution and speed this enables biologists to investigate such structures," said Thomas Huser. Another application for the new microscope is the investigation of virus particles on their way through the cell. "This enables us to understand exactly what happens during infection processes."

Publication: Andreas Markwirth, Rainer Heintzmann et al., Video-rate multi-color structured illumination microscopy with simultaneous real-time reconstruction, Nature Communications 10 (2019), https://doi.org/10.1038/s41467-019-12165-x

Source: Leibniz IPHT

Here is the original post:
Super Resolution - posted by Biophotonics.World at Biophotonics.World - Biophotonics.World

Cell Imagers Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 – Bulletin Line

New Jersey, United States,- This detailed market research covers the growth potential of the Cell Imagers Market, which can help stakeholders understand the key trends and prospects of the Cell Imagers market and identify growth opportunities and competitive scenarios. The report also focuses on data from other primary and secondary sources and is analyzed using a variety of tools. This will help investors better understand the growth potential of the market and help investors identify scope and opportunities. This analysis also provides details for each segment of the global Cell Imagers market.

The report was touted as the most recent event hitting the market due to the COVID-19 outbreak. This outbreak brought about a dynamic change in the industry and the overall economic scenario. This report covers the analysis of the impact of the COVID-19 pandemic on market growth and revenue. The report also provides an in-depth analysis of the current and future impacts of the pandemic and post-COVID-19 scenario analysis.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The market is further segmented on the basis of types and end-user applications. The report also provides an estimation of the segment expected to lead the market in the forecast years. Detailed segmentation of the market based on types and applications along with historical data and forecast estimation is offered in the report.

Furthermore, the report provides an extensive analysis of the regional segmentation of the market. The regional analysis covers product development, sales, consumption trends, regional market share, and size in each region. The market analysis segment covers forecast estimation of the market share and size in the key geographical regions.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

Global Cell Imagers Market, By Product

Equipment Consumables Software

Global Cell Imagers Market, By Application

Drug Discovery Developmental Biology Cell Biology Stem Cell Biology

Global Cell Imagers Market, By End User

Academic & Research Institutes Pharmaceutical & Biotechnology Companies Academic & Research Institutes

On the basis of regional segmentation, the market is bifurcated into major regions ofNorth America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.The regional analysis further covers country-wise bifurcation of the market and key players.

The research report offered by Verified Market Research provides an updated insight into the global Cell Imagers market. The report covers an in-depth analysis of the key trends and emerging drivers of the market likely to influence industry growth. Additionally, the report covers market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market.

Highlights of the TOC of the Cell Imagers Report:

Overview of the Global Cell Imagers Market

Market competition by Players and Manufacturers

Competitive landscape

Production, revenue estimation by types and applications

Regional analysis

Industry chain analysis

Global Cell Imagers market forecast estimation

This Cell Imagers report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Key Questions Addressed in the Report:

What are the key driving and restraining factors of the global Cell Imagers market?

What is the concentration of the market, and is it fragmented or highly concentrated?

What are the major challenges and risks the companies will have to face in the market?

Which segment and region are expected to dominate the market in the forecast period?

What are the latest and emerging trends of the Cell Imagers market?

What is the expected growth rate of the Cell Imagers market in the forecast period?

What are the strategic business plans and steps were taken by key competitors?

Which product type or application segment is expected to grow at a significant rate during the forecast period?

What are the factors restraining the growth of the Cell Imagers market?

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

More here:
Cell Imagers Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 - Bulletin Line

Live-Cell Imaging Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 – Bulletin Line

New Jersey, United States,- This detailed market research covers the growth potential of the Live-Cell Imaging Market, which can help stakeholders understand the key trends and prospects of the Live-Cell Imaging market and identify growth opportunities and competitive scenarios. The report also focuses on data from other primary and secondary sources and is analyzed using a variety of tools. This will help investors better understand the growth potential of the market and help investors identify scope and opportunities. This analysis also provides details for each segment of the global Live-Cell Imaging market.

The report was touted as the most recent event hitting the market due to the COVID-19 outbreak. This outbreak brought about a dynamic change in the industry and the overall economic scenario. This report covers the analysis of the impact of the COVID-19 pandemic on market growth and revenue. The report also provides an in-depth analysis of the current and future impacts of the pandemic and post-COVID-19 scenario analysis.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The market is further segmented on the basis of types and end-user applications. The report also provides an estimation of the segment expected to lead the market in the forecast years. Detailed segmentation of the market based on types and applications along with historical data and forecast estimation is offered in the report.

Furthermore, the report provides an extensive analysis of the regional segmentation of the market. The regional analysis covers product development, sales, consumption trends, regional market share, and size in each region. The market analysis segment covers forecast estimation of the market share and size in the key geographical regions.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

Global Live-Cell Imaging Market, By Product

Instruments Consumables Software

Global Live-Cell Imaging Market, By Application

Drug Discovery Developmental Biology Cell Biology Stem Cell Biology

Global Live-Cell Imaging Market, By End User

Academic & Research Institutes Pharmaceutical & Biotechnology Companies Academic & Research Institutes

On the basis of regional segmentation, the market is bifurcated into major regions ofNorth America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.The regional analysis further covers country-wise bifurcation of the market and key players.

The research report offered by Verified Market Research provides an updated insight into the global Live-Cell Imaging market. The report covers an in-depth analysis of the key trends and emerging drivers of the market likely to influence industry growth. Additionally, the report covers market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market.

Highlights of the TOC of the Live-Cell Imaging Report:

Overview of the Global Live-Cell Imaging Market

Market competition by Players and Manufacturers

Competitive landscape

Production, revenue estimation by types and applications

Regional analysis

Industry chain analysis

Global Live-Cell Imaging market forecast estimation

This Live-Cell Imaging report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Key Questions Addressed in the Report:

What are the key driving and restraining factors of the global Live-Cell Imaging market?

What is the concentration of the market, and is it fragmented or highly concentrated?

What are the major challenges and risks the companies will have to face in the market?

Which segment and region are expected to dominate the market in the forecast period?

What are the latest and emerging trends of the Live-Cell Imaging market?

What is the expected growth rate of the Live-Cell Imaging market in the forecast period?

What are the strategic business plans and steps were taken by key competitors?

Which product type or application segment is expected to grow at a significant rate during the forecast period?

What are the factors restraining the growth of the Live-Cell Imaging market?

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

More here:
Live-Cell Imaging Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 - Bulletin Line

Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse Immunotherapy to Treat HPV-associated Cancers -…

GERMANTOWN, Md., Aug. 17, 2020 /PRNewswire/ -- Precigen, Inc.(Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen's PRGN-2009, a first-in-class,off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse platform designed to activate the immune system to recognize and target HPV+ solid tumors (clinical trial identifier: NCT04432597). HPV-associatedcancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.

ThePhase I portion of the study will use 3+3 dose escalation to evaluate the safety of PRGN-2009 administered as a monotherapy and to determine the recommended Phase II dose (R2PD) followed by an evaluation of the safety of the combination of PRGN-2009 at the R2PD and bintrafusp alfa (M7824), an investigational bifunctional fusion protein, in patients with recurrent or metastatic HPV-associated cancers. The Phase II portion of the study will evaluate PRGN-2009 as a monotherapy or in combination with bintrafusp alfa as a neoadjuvant or induction therapy in patients with newly-diagnosed stage II/III HPV16-positive oropharyngeal cancer.

PRGN-2009 leverages Precigen's proprietary UltraVector and AdenoVerse platforms to optimize HPV antigen design. Such design is differentiated from other therapies due to the gorilla adenovector's large payload capacity and potential for repeat administration due to very low to no seroprevalence in the human population.

PRGN-2009 is under development through a Cooperative Research and Development Agreement, or CRADA, with the laboratory of Dr. Jeffrey Schlom, Chief oftheLaboratory of Tumor Immunology and Biology (LTIB), Center for Cancer Research (CCR),National Cancer Institute (NCI). This CRADA has allowed Precigen to rapidly and cost-effectively advance PRGN-2009.The Phase I/II clinical trial of PRGN-2009 is being conducted at the NIH Clinical Center and will be led by Dr. Julius Strauss, Co-Director of the LTIB's Clinical Trials Group, and Dr. James Gulley, Chief of the Genitourinary Malignancies Branch, CCR, NCI. For patients interested in enrolling in this clinical study, please call NCI's toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email NCIMO_Referrals@mail.nih.gov,and/or visit the website:https://trials.cancer.gov.

"We appreciate working in collaboration with such renowned partners at the NCI to achieve this important milestone in our efforts to develop a new off-the-shelf immunotherapy treatment option for patients with HPV-associated cancers," said Helen Sabzevari, PhD, President and CEO of Precigen. "We are excited to investigate Precigen's proprietary gorilla adenovector platform for the first time in a clinical setting and achieve this milestone during the COVID-19 global pandemic."

About HPV-associated CancersHPV infects the squamous cells that line the inner surfaces of certain organs and, consequently, most HPV-related cancers are a type of cancer called squamous cell carcinoma. Some cervical cancers come from HPV infection of gland cells in the cervix and are referred to as adenocarcinomas.1 HPV-related cancers include cervical, oropharyngeal, anal, penile, vaginal, and vulvar.1 Nearly 44,000 HPV-associated cancers occur in the United States each year. Of these, approximately 25,000 occur in women and 19,000 occur in men.2HPV is considered responsible for more than 90% of analand cervicalcancers, about 70% of vaginal and vulvar cancers, and more than 60% of penile cancers.2 Recent studies indicate that about 70% of cancers of the oropharynxalso may be related to HPV.2

Precigen: Advancing Medicine with PrecisionPrecigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

For more information about Precigen, visit http://www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

References1HPV and Cancer, National Institutes of Health. Accessed in July 20202 HPV-Associated Cancer Statistics, Centers for Disease Control and Prevention. Accessed in July 2020

TrademarksPrecigen, AdenoVerse, UltraVector, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor StatementSome of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical and clinical trials and discovery programs, the promise of the Company's portfolio of therapies, the Company's refocus to a healthcare-oriented business, and its continuing evaluation of options for the Company's non-healthcare businesses. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trial might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:

Steven Harasym

Vice President, Investor Relations

Tel: +1 (301) 556-9850

investors@precigen.com

Media Contact:

Marie Rossi, PhD

Vice President, Communications

Tel: +1 (301) 556-9850

press@precigen.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-announces-first-patient-dosed-in-phase-iii-study-of-first-in-class-prgn-2009-adenoverse-immunotherapy-to-treat-hpv-associated-cancers-301112945.html

SOURCE Precigen, Inc.

See the rest here:
Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse Immunotherapy to Treat HPV-associated Cancers -...

HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19 – BioSpace

Aug. 17, 2020 12:05 UTC

Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling technology to identify, engineer, and evaluate multiple neutralizing antibodies against SARS-CoV-2

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- HiFiBiO, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, today announced a collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance headquartered at the La Jolla Institute for Immunology (LJI). CoVIC was established to accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2. It has received support from the COVID-19 Therapeutics Accelerator, which was launched in March 2020 by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with additional funding from a range of donors.

Using a combination of its proteomics and proprietary single-cell profiling technology, HiFiBiO has developed multiple SARS-CoV-2 neutralizing antibodies with the potential for both therapeutic and prophylactic applications. With an aligned commitment to deliver accessible therapies to vulnerable individuals globally, the company has submitted 10 distinct antibodies in the format of mono- or bispecific antibodies to CoVIC for in vitro and in vivo testing. HiFiBiO will gain a first look into the performance of its antibodies compared to dozens of other submitted antibodies and synergies among them for combinational therapies.

CoVIC is committed to accelerating the product development pipeline to provide immunotherapeutics that protect vulnerable individuals from severe COVID-19 across the globe, especially in regions where health care resources are severely limited, said Erica Ollmann Saphire, PhD, Professor at LJIs Center for Infectious Diseases and Vaccine Research and Director of CoVIC. We are excited to partner with HiFiBiO to include its antibodies against SARS-CoV-2 in the CoVIC panel that will be analyzed side-by-side in multiple tests to identify optimal immunotherapeutics for COVID-19 patients.

We look forward to working with CoVIC to further assess the potential of our neutralizing antibodies against SARS-CoV-2, said Liang Schweizer, PhD, President and CEO of HiFiBiO Therapeutics. This collaboration is another strong validation of our Drug Intelligent Science platform and our ongoing commitment to working with leading research and academic institutions, as well as pharmaceutical and biotech companies to identify and engineer highly potent and durable antibodies that can address unmet medical needs of patients around the world.

Additionally, HiFiBiO Therapeutics is preparing an Investigational New Drug (IND) application with the US Food and Drug Administration for HFB30132A, a novel SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients. The highly differentiated antibody has been rapidly identified, engineered, and evaluated in all key preclinical studies, where it has demonstrated outstanding efficacy, exposure, and safety profile. A planned Phase I single-IV administration ascending dose study will assess the safety and tolerability of HFB30132A in healthy volunteers later this summer.

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The companys strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai, and Hong Kong. To learn more, please visit http://www.hifibio.com.

HiFiBiO Therapeutics and the HiFiBiO Therapeutics logo are trademarks of HiFiBiO and its affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005087/en/

Link:
HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19 - BioSpace

What are the Differences Between Small Cell and Non-Small Cell Lung Cancer? – News-Medical.net

Throughout the world, lung cancer is the main cause of cancer-related deaths. Whereas small cell lung cancer (SCLC) accounts for up to 15% of all lung cancer diagnoses, the remaining 85% of lung cancer cases are of the non-small cell lung cancer (NSCLC) subtype.

Image Credit: David A Litman/Shutterstock.com

Non-small cell lung cancer (NSCLC) can be further categorized into several different types, the most common of which include adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma. Other less common types of NSCLC include adenosquamous, pleomorphic, spindle cell, and giant cell carcinomas, as well as pulmonary blastoma, neuroendocrine tumors, and several others.

Recent advancements in molecular biology, particularly due to the discovery of epidermal growth factor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, have drastically changed how these NSCLC subtypes are treated. These discoveries have led to the development of EGFR tyrosine kinase inhibitors and ALK inhibitors, both of which are highly effective treatment options for patients with these specific histologic types of lung cancer.

It is estimated that adenocarcinomas comprise approximately 40% of all lung cancers. By definition, adenocarcinoma in the lung is a malignant epithelial neoplasm that can be accompanied by either glandular differentiation or the production of mucin. Typically, an adenocarcinoma will form a peripherally located mass that exhibits both central fibrosis and pleural puckering.

Other gross appearances that can be associated with an adenocarcinoma diagnosis include a centrally located mass, diffuse lobar consolidation, multiple lobes distributed bilaterally, and pleural thickening.

Following a biopsy or tumor resection, an adenocarcinoma can be further characterized as a lepidic, acinar, papillar, micropapillary, solid, invasive mucinous, colloid, fetal, enteric, or minimally invasive carcinoma.

Approximately 20% of all lung cancers are SCC, which can be present in various places throughout the lungs, the most common of which include the central portion, along major airways and in the form of cavities when present in larger sizes.

Some of the notable pathological characteristics of SCC include keratinization and intracellular bridges, as well as a solid nested growth pattern. The possible subtypes of SCCs include keratinizing, nonkeratinizing, and basaloid SCC.

The establishment of an SCC diagnosis plays a determining role in which chemotherapeutic agents are not only ideal in reducing the cancer burden but can also avoid certain life-threatening complications. The use of a vascular endothelial growth factor inhibitor in the treatment of SCC, for example, can increase the likelihood of a pulmonary hemorrhage, thereby indicating the need to avoid this type of drug.

Notably, patients with SCC often have a better survival rate as compared to those diagnosed with adenocarcinoma.

The establishment of a large cell carcinoma diagnosis can only be achieved after the tumor has been resected; therefore, this type of NSCLC should not be applied to small biopsies or cytology results. There are several different subtypes of large cell carcinoma including large cell neuroendocrine carcinoma (LCNEC), basaloid carcinoma, lymphoepithelioma-like carcinoma, clear cell carcinoma, and large cell carcinoma with rhabdoid phenotype.

Recent reports by the World Health Organization (WHO) have found that large cell carcinomas are a heterogeneous group of tumors that can be made up of adenocarcinoma, squamous cell differentiation, or a null immunophenotype and genotype.

Image Credit: Scio21/Shutterstock.com

Over the past twenty years, the incidence of SCLC has decreased, which is most likely related to the global reduction in tobacco use. It is estimated that at least 95% of patients diagnosed with SCLC have a positive smoking history; however, individuals who quit smoking not only have a reduced incidence of the disease but also have a 50% chance of reduced mortality when this type of lung cancer is diagnosed in its early stages.

In addition to a history of smoking, other environmental and occupational hazards that have been associated with causing SCLC to include exposure to chloromethyl ether, which is a chemical that can be used in various industrial settings, as well as high radon levels, which is particularly a concern for uranium miners.

Although SCLC only comprises about 15% of all lung cancer diagnoses, this form of lung cancer is highly aggressive. In addition, since many patients with SCLC also have multiple comorbidities due to previous tobacco use, which can include chronic obstructive pulmonary disease (COPD), ischemic cardiopathy, and hypertension, treatment for this type of lung cancer can be highly complicated.

Whereas patients with limited disease (LD) type of SCLC is often treated with concomitant chemoradiation, those with the extensive disease (ED) type are instead treated with palliative chemotherapy. Many patients with SCLC will respond well to initial treatment; however, it is common for patients with the resistant disease to relapse.

In the event that the cancer relapses, the median survival is typically in the range of 4 to 5 months when second- or third-line chemotherapy is used.

Link:
What are the Differences Between Small Cell and Non-Small Cell Lung Cancer? - News-Medical.net

A genetic map hopes to trace rescued chimps back to their homes – Mongabay.com

Experts estimate that nearly 2,000 chimpanzees may be lost to the wildlife trade each year. Once taken from the wild, young chimpanzees that survive the trauma of capture are sold as pets or for entertainment and can end up almost anywhere; theyve been intercepted by authorities in locations all over the globe.

Theyre confiscated in maybe Moscow, or San Francisco, or Hong Kong it can be anywhere and we dont know where they came from, says Peter Frandsen, a conservation genomics researcher at Copenhagen Zoo in Denmark.

Thats a problem when conservationists need to decide which countrys sanctuaries an animal should return to or where it could be safely reintroduced into the wild.

The answer may lie in the chimpanzees own genetic code. A global team of researchers is working to determine how chimpanzee genetics vary based on where the animals come from. By creating this genetic reference map, scientists hope to be able to determine the origins of confiscated chimpanzees as well as identify high-risk areas for wildlife trafficking.

Just a century ago, a million chimpanzees roamed the rainforests and grasslands of Africa. Now, fewer than 200,000 may be left in the wild, and conservationists fear that without widespread change these animals may go extinct in their natural habitats.

Pretty much all of the big conservation threats are facing chimpanzees right now, says Mimi Arandjelovic, a primatologist at the Max Planck Institute for Evolutionary Anthropology in Germany. Logging, mining, all of the extractive industries that are going on in equatorial Africa And then of course theres the huge threat of disease Theres the bushmeat trade, so people hunt and eat apes. And theres the primate pet trade.

Chimpanzees are currently listed as endangered by the IUCN (the western chimpanzee, one of four subspecies, is listed as critically endangered), and their numbers are still declining.

While chimpanzee conservation has many components, researchers say genetic studies are an increasingly important piece of the conservation puzzle.

One recently published study sheds new light on just how valuable genetic information could be in the conservation of this endangered species.

In this study, a group of researchers from Denmark, Spain, Russia and the U.K. analyzed nearly 60,000 ancestry-related genetic markers from captive-born and wild-born chimpanzees. In collaboration with dozens of zoos and sanctuaries across Europe and Africa, the researchers used hair samples to source DNA, a technique that is less invasive and stressful for animals than collecting blood.

Using the genetic data from wild-born chimpanzees whose birthplace was known, the researchers constructed a genetic reference map. They then compared this map with the DNA from chimpanzees who ended up in sanctuaries after being confiscated from illegal wildlife trafficking operations. In this way, researchers were able to estimate where the sanctuary chimpanzees had come from.

So just like popular DNA testing services for humans can tell us about our ancestry and origins, genetic information can reveal where chimpanzees come from.

Frandsen, one of the study authors, says learning where chimpanzees come from is important for many reasons.

For example, he says, genetic analysis provides essential information for captive-breeding programs. Even though chimpanzees may all look similar, there are actually four different accepted subspecies (and a fifth proposed subspecies), each with their own distinct range and unique genetic makeup. But there arent always records about where animals come from and which subspecies they are, which makes it difficult for captive-breeding programs to maintain the integrity of subspecies.

Frandsen says its important for captive-breeding programs to preserve these unique subspecies. Modern zoos are often referred to as Noahs Arks. You could call it a living museum sample, he says. So, we want to make sure that [zoo populations] resemble what you would find in the wild.

That way, he says, if a subspecies goes extinct in the wild, it wouldnt be lost altogether and eventually individuals of that subspecies could be reintroduced to the wild from these captive populations.

But genetic information may be even more valuable for combating animal trafficking.

Arandjelovic, who was not involved in the 2020 study by Frandsen and colleagues, says its unfortunately common for people to kill chimpanzee mothers for bushmeat and sell the babies as pets. Chimpanzees that are recovered from this wildlife trade can be candidates for reintroduction into the wild, so knowing where they came from is essential for deciding where they should be released.

Although Frandsen acknowledges that reintroduction can be challenging, especially as animals get older, he says its still very important. Theyre filling up in the sanctuaries, they dont have enough space and one of the main goals is to reintroduce as many as they can, he says. The sanctuary shouldnt be the endpoint for these chimpanzees if theres an opportunity to relocate them. Determining where an animal came from using genetic data may give it a better chance at a successful return to the wild.

Its possible that genetic data could even help prevent chimpanzee trafficking altogether. Identifying where chimpanzees in the illegal pet trade have come from could reveal poaching hotspots, thus allowing countries to appropriately target anti-poaching efforts. This is especially important in places where conservation funding may be limited.

But Frandsen says they dont yet have enough data to identify these high-risk areas. In this early proof-of-principle project, researchers analyzed just a few dozen animals that were rescued from the wildlife trade and ended up in sanctuaries. Frandsen says there are about 1,000 chimpanzees currently in African sanctuaries; the research team wants to expand their data collection to include these animals so that they can build a more accurate picture of poaching hotspots.

Future projects also include collecting more data from individuals born at known locations to build a more detailed genetic reference map, Frandsen says. The more detailed this map is, the more accurately researchers can determine where a trafficked animal has been taken from.

For some of the subspecies, we have pretty good data from the wild, Frandsen says. But for some of the other subspecies we are still data-deficient. So right now, the plan is to fill those knowledge gaps on the map.

Arandjelovic agrees that having accurate and detailed genetic reference maps is very important for determining the provenance of apes confiscated from the pet trade. She says the technique used in the present study analyzing thousands of different markers provides very detailed information about an individual. However, because of the cost and the specialized supplies needed to run this sort of analysis, it often cannot be done in the chimpanzees country of origin.

She says she wants to see if a reference map could be built using a simpler and cheaper technique that analyzes fewer locations in the genome. This technique would have the advantage of being more feasible to carry out in the countries where chimpanzees live. It would be great if we didnt have to export the samples, if we could do everything in-country, she says. That would be faster (we dont have to deal with permits), but we can also start capacity-building and having people in the country of origin do that work instead of sending it to Europe or North America. On the other hand, its not yet clear if this simpler technique would provide enough genetic information to create a useful reference map.

Frandsen and Arandjelovic agree that this is just the beginning for the application of genetic techniques to locate the origins of trafficked animals. The present study is a proof of concept, Frandsen says. So, theres a lot of work ahead to complete this project, but this is just for the chimpanzees, he says. Its also really a blueprint for other conservation projects. There are a ton of other taxa that this could be applied to.

Citation:

FEEDBACK: Use this form to send a message to the author of this post. If you want to post a public comment, you can do that at the bottom of the page.

More here:
A genetic map hopes to trace rescued chimps back to their homes - Mongabay.com

Consistent associations between human genetic variation and the gut microbiome identified in 3 independent European cohorts – Gut Microbiota for…

Many thousands of studies about gut microbiota and 16s RNA analysis are available to us nowadays. And while many results and interesting concepts emerge from those studies, a gold standard protocol for data analysis is not yet available. Moreover, the studies are carried out by different teams from different parts of the world, their designs are not the same, DNA extraction protocols differ, and 16s RNA region sequences vary between projects. As such, sample processing variables and the numerous environmental factors influencing an individuals gut microbiota mean association studies between the human genome and gut microbiota genome are less powerful.

Writing in Nature Microbiology, David A. Hughes and colleagues have created a new analytical pipeline that disentangles associations between human host genotype and gut microbiome variation in 3 distinct cohorts, paving the way for causal inference analyses in the field.

Researchers harmonized the analytical pipeline across three independent cohorts: the Flemish Gut Flora Project (n = 2,223) and two German cohorts (Food-Chain Plus, n=950; and PopGen, n= 717).

Using fecal 16s RNA gene sequencing, the researchers first estimated the proportion of gut microbiome variation explained by genetic variation (heritability) between individuals. In total, they identified 13 genera that were heritable. Eight were from the phylum Firmicutes, five of which were from the family Lachnospiraceae and two from Ruminococcaceae.

Dorea and Anaerostipes genera, which are short-chain fatty acid producers, along with Hespellia were three of the most heritable bacteria.

During a second stage, the researchers identified associations between bacteria species and human genes, encountering two strong associations:

The two strong associations were followed by the discovery of 11 associations showing low heterogeneity. Among those 11 associations, they found a relationship between the butyrate-producing genus Butyricicoccus and the SLC5A11 gene, which is a sodium-dependent myo-inositol glucose cotransporter that is highly expressed in the brain and intestine. The findings are in agreement with previous studies suggesting that butyrate-producing bacteria are associated with blood glucose and appetite regulation.

Another association was identified between Veillonella and rs117338748. This gene is involved in regulating low-density lipoproteins (LDLs) and transporting high-density lipoproteins (HDLs). The researchers observed that the presence of Veillonella was associated with a drop in LDL-cholesterol.

Using a Mendelian randomization model, the researchers estimated relationships between 5 microbial pathways and 7 outcomes (diseases). For instance, Bifidobacterium was associated with body composition. However, in the absence of clear microbiome-driven effects, any interpretation requires caution. In other words, it could be the causeless Bifidobacterium means the individual has a higher body mass index (BMI)or the consequencean individual with a higher BMI will present less Bifidobacterium in their gut.

In conclusion, this in-depth study on human genome-gut microbiome associations in 3 distinct cohorts generated a growing catalogue of genetic associations and showed better associations between the hosts genetics and its gut microbiota. Next steps should look at understanding the causation factors for a better understanding of gut microbiota function and association with outcomes.

Reference:

Hughes DA, Bacigalupe R, Wang J, et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat Microbiol. 2020. doi: 10.1038/s41564-020-0743-8.

Follow this link:
Consistent associations between human genetic variation and the gut microbiome identified in 3 independent European cohorts - Gut Microbiota for...

Evaluating the Role of Genetics in Pediatric Suicidal Ideation and Aggression – Psychiatry Advisor

Genetic variation combined with elevated aggression scores may predict childhood suicidal thoughts, while suicidal thoughts in childhood may point to young adult depression, according to data published in the Journal of Affective Disorders.

Researchers at the University of Pennsylvania wanted to determine if suicidal ideation in childhood was associated with genes indicative of suicidal ideation in adults. They also wanted to determine if aggression played a role in childhood suicidal thoughts.

A psychiatric disorder is present in more than 90% of adult suicides, according to the investigators, and aggression is associated with increased suicidal behaviors in both children and adults. Uncovering the role of childhood suicidal behavior on the development of psychiatric disorders later in life, as well as the influence of aggression, could help with suicide prevention efforts.

A total of 478 participants aged 8 through 18 years enrolled in the study and received ongoing assessment until age 19. Using multiple behavior assessment tools, researchers found that 25.9% of participants reported suicidal thoughts during 1 or more visits. These thoughts occurred for the first time at a median age of 13 years (mean age, 12.72.9 years; range, 8-18 years). Of the 17 children that attempted suicide, 10 reported aggression. Results of a Cox Survival analysis demonstrated a significant association between childhood aggression and suicide attempts.

To determine the role of genetics in the onset of suicidal thoughts, investigators tested specific haplotypes within ANKK1-DRD2 and HTR2C as potential predictors of suicidal thoughts and behaviors. Structural equation model results demonstrated that 3 single nucleotide polymorphisms (SNPs) within the HTR2C gene, 1 SNP in the ANKK1 gene, and 2 haplotypes AAAC in the ANKK1-DRD2 complex and the CCC haplotype in the HTR2C gene were significantly associated with suicidal ideation in childhood.

Limitations of the study include the relatively small sample size and the use of assessments conducted between 1990 and 2010, which does not account for the rise in suicide rates over the past decade.

Using genetic sequencing, researchers found specific haplotypes within ANKK1-

DRD2 and HTR2C genes are associated with either risk or resilience to developing suicidal

thoughts in childhood, depending on the individuals genetic background. Determining overall levels of aggression further helps determine which children will develop suicidal thoughts.

These observations have the potential to provide a framework for precision medicine that utilizes both genetic variation and phenotypic markers for early intervention and treatment, the researchers concluded.

Reference

Hill SY, Jones BL, Haas GL. Suicidal ideation and aggression in childhood, genetic variation and young adult depression [published online July 24, 2020]. J Affect Disord. doi: 10.1016/j.jad.2020.07.049

Continued here:
Evaluating the Role of Genetics in Pediatric Suicidal Ideation and Aggression - Psychiatry Advisor